Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the IPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Apr 22

PMID 25895984

Citations 48

Authors

Monica Gandhi

David V Glidden

Albert Liu

Peter L Anderson

Howard Horng

Patricia Defechereux

Juan V Guanira

Beatriz Grinsztejn

Suwat Chariyalertsak

Linda-Gail Bekker

Robert M Grant

Affiliations

Soon will be listed here.

Abstract

Self-reported adherence to pre-exposure prophylaxis (PrEP) has limitations, raising interest in pharmacologic monitoring. Drug concentrations in hair and dried blood spots (DBS) are used to assess long-term-exposure; hair shipment/storage occurs at room temperature. The iPrEx Open Label Extension collected DBS routinely, with opt-in hair collection; concentrations were measured with liquid chromatography/tandem mass spectrometry. In 806 hair-DBS pairs, tenofovir (TFV) hair levels and TFV diphosphate (DP) in DBS were strongly correlated (Spearman coefficient r = 0.734; P < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .001); hair FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001). Drug detectability was generally concordant by matrix. Hair TFV/FTC concentrations correlate strongly with DBS levels, which are predictive of PrEP outcomes.

Citing Articles

Prepared, Protected, EmPowered (P3): Primary Results of a Randomized Controlled Trial Using a Social Networking, Gamification, and Coaching App to Promote Pre-exposure Prophylaxis (PrEP) Adherence for Sexual and Gender Minority (SGM) Youth Living in....

Hightow-Weidman L, Rainer C, Schader L, Rosso M, Benkeser D, Cottrell M AIDS Behav. 2024; 29(2):652-663.

PMID: 39531118 DOI: 10.1007/s10461-024-04547-0.

Enhancing HIV pre-exposure prophylaxis outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform: protocol for a cluster-randomized controlled trial.

Lagat H, Pintye J, Harrington E, Houck S, Kwena Z, Lenn M Trials. 2024; 25(1):394.

PMID: 38890744 PMC: 11186170. DOI: 10.1186/s13063-024-08206-6.

Lessons Learned From the Implementation of a Pilot Study on Self-collected Specimen Return by Sexual Minority Men (Project Caboodle!): Qualitative Exploration.

Sallabank G, Stephenson R, Gandhi M, Merrill L, Sharma A JMIR Form Res. 2023; 7:e43539.

PMID: 37023442 PMC: 10131702. DOI: 10.2196/43539.

PrEPare for Work: A Pilot Randomized Controlled Trial of an Intervention to Optimize HIV PrEP Outcomes Among Male Sex Workers.

Biello K, Chan P, Holcomb R, Daley Ndoye C, Valente P, Maynard M AIDS Behav. 2023; 27(10):3294-3305.

PMID: 36976389 PMC: 10753039. DOI: 10.1007/s10461-023-04050-y.

Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.

Bazzi A, Bordeu M, Baumgartner K, Sproesser D, Bositis C, Krakower D BMC Public Health. 2023; 23(1):513.

PMID: 36932369 PMC: 10021034. DOI: 10.1186/s12889-023-15429-w.

References

Gandhi M, Yang Q, Bacchetti P, Huang Y . Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses. 2013; 30(1):25-8. PMC: 3887402. DOI: 10.1089/aid.2013.0239. View

Baxi S, Liu A, Bacchetti P, Mutua G, Sanders E, Kibengo F . Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2014; 68(1):13-20. PMC: 4262724. DOI: 10.1097/QAI.0000000000000386. View

Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

Anderson P, Glidden D, Liu A, Buchbinder S, Lama J, Guanira J . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra125. PMC: 3721979. DOI: 10.1126/scitranslmed.3004006. View

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

Podsadecki T, Vrijens B, Tousset E, Rode R, Hanna G . "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008; 9(4):238-46. DOI: 10.1310/hct0904-238. View

Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

10.

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

11.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

12.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

13.

Coetzee B, Kagee A, Tomlinson M, Warnich L, Ikediobi O . Reactions, beliefs and concerns associated with providing hair specimens for medical research among a South African sample: a qualitative approach. Future Virol. 2013; 7(11):1135-1142. PMC: 3640774. DOI: 10.2217/fvl.12.100. View

14.

Liu A, Yang Q, Huang Y, Bacchetti P, Anderson P, Jin C . Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. PMC: 3885443. DOI: 10.1371/journal.pone.0083736. View

15.

Hickey M, Salmen C, Tessler R, Omollo D, Bacchetti P, Magerenge R . Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014; 66(3):311-5. PMC: 4146734. DOI: 10.1097/QAI.0000000000000154. View